Literature DB >> 8325895

Characterization of an arginine 789 to cysteine substitution in alpha 1 (II) collagen chains of a patient with spondyloepiphyseal dysplasia.

D Chan1, T K Taylor, W G Cole.   

Abstract

A child with spondyloepiphyseal dysplasia congenita was shown to be heterozygous for a mutation of the COL2A1 gene that encodes the alpha 1 (II) chain of type II collagen. The alpha 1 (II) chains extracted from cartilage contained disulfide-bonded dimeric and trimeric alpha 1 (II) chains. Carboxymethylation confirmed that some of the type II collagen chains contained cysteine residues that are not normally present in alpha 1 (II) chains. Cyanogen bromide peptide mapping showed that the abnormal cysteine residue was located in the alpha 1 (II) CB10.5 peptide. Amplification products of the corresponding region of alpha 1 (II) cDNA prepared from cultured dermal fibroblasts were shown by chemical cleavage and single strand conformation polymorphism analyses to contain a sequence anomaly. DNA sequencing showed a transition of C2913T in exon 41 of one allele of the COL2A1 gene resulting in the substitution of arginine 789 by cysteine in the alpha 1 (II) chain. The mutation resulted in the loss of a MaeII cleavage site that was used to confirm that the proband was heterozygous for the mutation and that neither parent showed evidence of the mutation. The type II collagen extracted from cartilage and from chondrocytes cultured in alginate beads showed similar characteristics. Approximately a third of the type II collagen chains were mutant, and the secretion of molecules containing mutant chains was impaired. The thermal stability of the collagen extracted from cartilage was normal. This study confirmed the importance of dominant negative mutations of the COL2A1 gene in producing the spondyloepiphyseal dysplasia congenita phenotype.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8325895

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  The expanding spectrum of COL2A1 gene variants IN 136 patients with a skeletal dysplasia phenotype.

Authors:  Mouna Barat-Houari; Bruno Dumont; Aurélie Fabre; Frédéric Tm Them; Yves Alembik; Jean-Luc Alessandri; Jeanne Amiel; Séverine Audebert; Clarisse Baumann-Morel; Patricia Blanchet; Eric Bieth; Marie Brechard; Tiffany Busa; Patrick Calvas; Yline Capri; François Cartault; Nicolas Chassaing; Vidrica Ciorca; Christine Coubes; Albert David; Anne-Lise Delezoide; Delphine Dupin-Deguine; Salima El Chehadeh; Laurence Faivre; Fabienne Giuliano; Alice Goldenberg; Bertrand Isidor; Marie-Line Jacquemont; Sophie Julia; Josseline Kaplan; Didier Lacombe; Marine Lebrun; Sandrine Marlin; Dominique Martin-Coignard; Jelena Martinovic; Alice Masurel; Judith Melki; Monique Mozelle-Nivoix; Karine Nguyen; Sylvie Odent; Nicole Philip; Lucile Pinson; Ghislaine Plessis; Chloé Quélin; Elise Shaeffer; Sabine Sigaudy; Christel Thauvin; Marianne Till; Renaud Touraine; Jacqueline Vigneron; Geneviève Baujat; Valérie Cormier-Daire; Martine Le Merrer; David Geneviève; Isabelle Touitou
Journal:  Eur J Hum Genet       Date:  2015-12-02       Impact factor: 4.246

2.  The phenotypic spectrum in patients with arginine to cysteine mutations in the COL2A1 gene.

Authors:  K P Hoornaert; C Dewinter; I Vereecke; F A Beemer; W Courtens; A Fryer; H Fryssira; M Lees; A Müllner-Eidenböck; D L Rimoin; L Siderius; A Superti-Furga; K Temple; P J Willems; A Zankl; C Zweier; A De Paepe; P Coucke; G R Mortier
Journal:  J Med Genet       Date:  2005-09-09       Impact factor: 6.318

3.  An alpha 2 collagen VIII transgenic knock-in mouse model of Fuchs endothelial corneal dystrophy shows early endothelial cell unfolded protein response and apoptosis.

Authors:  Albert S Jun; Huan Meng; Naren Ramanan; Mario Matthaei; Shukti Chakravarti; Richard Bonshek; Graeme C M Black; Rhonda Grebe; Martha Kimos
Journal:  Hum Mol Genet       Date:  2011-10-14       Impact factor: 6.150

4.  Report of five novel and one recurrent COL2A1 mutations with analysis of genotype-phenotype correlation in patients with a lethal type II collagen disorder.

Authors:  G R Mortier; M Weis; L Nuytinck; L M King; D J Wilkin; A De Paepe; R S Lachman; D L Rimoin; D R Eyre; D H Cohn
Journal:  J Med Genet       Date:  2000-04       Impact factor: 6.318

5.  Classical Ehlers-Danlos syndrome caused by a mutation in type I collagen.

Authors:  L Nuytinck; M Freund; L Lagae; G E Pierard; T Hermanns-Le; A De Paepe
Journal:  Am J Hum Genet       Date:  2000-03-17       Impact factor: 11.025

Review 6.  The triple helix of collagens - an ancient protein structure that enabled animal multicellularity and tissue evolution.

Authors:  Aaron L Fidler; Sergei P Boudko; Antonis Rokas; Billy G Hudson
Journal:  J Cell Sci       Date:  2018-04-09       Impact factor: 5.285

7.  Reducing the effects of intracellular accumulation of thermolabile collagen II mutants by increasing their thermostability in cell culture conditions.

Authors:  Katarzyna Gawron; Deborah A Jensen; Andrzej Steplewski; Andrzej Fertala
Journal:  Biochem Biophys Res Commun       Date:  2010-04-13       Impact factor: 3.575

8.  Abnormal type III collagen produced by an exon-17-skipping mutation of the COL3A1 gene in Ehlers-Danlos syndrome type IV is not incorporated into the extracellular matrix.

Authors:  A A Chiodo; D O Sillence; W G Cole; J F Bateman
Journal:  Biochem J       Date:  1995-11-01       Impact factor: 3.857

Review 9.  Genetic aspects of familial osteoarthritis.

Authors:  S A Jimenez; R M Dharmavaram
Journal:  Ann Rheum Dis       Date:  1994-12       Impact factor: 19.103

10.  A missense mutation in the mouse Col2a1 gene causes spondyloepiphyseal dysplasia congenita, hearing loss, and retinoschisis.

Authors:  Leah Rae Donahue; Bo Chang; Subburaman Mohan; Nao Miyakoshi; Jon E Wergedal; David J Baylink; Norman L Hawes; Clifford J Rosen; Patricia Ward-Bailey; Qing Y Zheng; Roderick T Bronson; Kenneth R Johnson; Muriel T Davisson
Journal:  J Bone Miner Res       Date:  2003-09       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.